0.07
0.07 (0%)
As of Aug 22, 2024
Vbi Vaccines Inc [VBIV]
Source:
Company Overview
VBI Vaccines Inc. (“VBI”) is a commercial stage biopharmaceutical company driven by immunology in the pursuit of powerful prevention and treatment of disease. Through its innovative approach to virus-like particles (“VLPs”), including a proprietary enveloped VLP (“eVLP”) platform technology, VBI develops vaccine candidates that mimic the natural presentation of viruses, designed to elicit the innate power of the human immune system.
| Country | United States |
| Headquarters | cambridge, massachusetts |
| Phone Number | 617-830-3031 |
| Industry | manufacturing |
| CEO | Jeffrey R. Baxter |
| Website | www.vbivaccines.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $1.2 |
| Operating Profit | $-11.8 |
| Net Income | $-17.9 |
| Net Cash | $-11.1 |
Profit Ratios
| Gross Margin | $-1.5 |
| Operating Margin | -968 |
| Profit as % of Revenues | 8.4% |
| Profit as % of Assets | -46.7% |
| Profit as % of Stockholder Equity | 327.4% |
Management Effectiveness
| Return on Equity | 327.4% |
| Return on Assets | -23.7% |
| Turnover Ratio | 3.2% |
| EBITA | $-11.8 |
Balance Sheet and Cash Flow Measures
| Total Assets | $75.4 |
| Total Liabilities | $80.9 |
| Operating Cash Flow | $-11.8 |
| Investing Cash Flow | $-0.2 |
| Financing Cash Flow | $0.8 |
